Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1187-1191

  Mata Marín, José Antonio ^a   Mata Marín, Luis Alberto ^b   Arroyo Anduiza, Carla Ileana ^c   Huerta García, Gloria ^c   Sandoval Ramirez J L ^a   Manjarrez Tellez, Bulmaro ^a   Gaytan Martinez J E ^a  

^a Hospital de Infectología   (Mexico)

^b Internal Medicine Department St Johannissitft Ev Krankenhaus Paderborn   (Germany)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Coinfection HBV HIV; HBV genotype H and G; HBV treatment; HIV treatment

Indexed keywords

EFAVIRENZ; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LOPINAVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RITONAVIR; TENOFOVIR; VIRUS DNA; ADENINE; ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; DEOXYCYTIDINE; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE G; HEPATITIS B VIRUS GENOTYPE H; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; MEXICO; MIXED INFECTION; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; HIV INFECTIONS; IMMUNOLOGY; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; COINFECTION; DEOXYCYTIDINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MEXICO; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84906988780     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge14359     Document Type: Article

References (20)

1. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009; 373:582-592.
2. Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl):S6-S9.
3. Mata Marín JA, Arroyo Anduiza CI, et al.: Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico. Ann Hepatol 2012; 11:47-51.
4. Thio CL, Seaberg EC, Skolasky R Jr., et al: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926. (Pubitemid 35472132)
5. Lada O, Gervais A, Branger M, et al.: Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of G genotype. Liver Int 2012; 32:93-101. doi: 10.1111/j.1478-3231.2011.02601.
6. Vigano M, Lampertico P: Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol 2012, 18:81-86.
7. Matthews G, Ali R, Avihingsanon A, et al: Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS ONE 2013; 8:e61297.
8. Lau GK, Piratvisuth T, Luo KX, Marcellin P, et al: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
9. Janssen HL, van Zonneveld M, Senturk H, et al.; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
10. Hagiwara S, Kudo M, Osaki Y, et al.: Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol 2013; 85:987-995. doi: 10.1002/jmv.23564.
11. Kittner JM, Sprinzl MF, Grambihler A, et al.: Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54:93-95. doi: 10.1016/j.jcv.2012.01.024.
12. Boyd A, Miailhes P, Maylin S, Gozlan J, Lascoux-Combe C, Delaugerre C, Girard PM, Lacombe K: Intensification with pegylated interferon during treatment with tenofovir in HIV/hepatitis B virus co-infected patients. CROI 2013 Paper #668.
13. Peng CY, Lai HC, Li YF, et al.: Early serum H BsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012; 35:458-468.
14. Kaplan JE, Benson C, Holmes KK, et al.: Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medical Association of Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-198.
15. Lok A, McMahon B: Chronic hepatitis B: Update 2009. AASLD Practice Guidelines 2009; 50:1-36.
16. Johnson RM, Ristig MB, Overton ET, et al.: Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals. HIV Clin Trials 2007; 8:173-181. (Pubitemid 47121762)
17. Doa D, Balko J, Attar N, et al.: Hepatitis B virus genotype G: prevalence and impact in patients co-infected with human immunodeficiency virus. J Med Virol 2011; 89:1551-1558. doi:10.1002/jmv.22160.
18. Osiowy C, Gordon D, Borlang J, Giles E, Villeneuve JP: Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol 2008; 89:3009-3015.
19. Lacombe K, Massari V, Girard PM, et al: Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Aids 2006; 20:419-427.
20. Roman S, Panduro A: HBV endemicity in Mexico is associated with HBV genotypes H y G. World J Gastroenterol 2013; 19:5446-5453.